Oxcarbazepine (Epilepsy)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8084
R24706		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.86 [0.03;115.45] C
excluded (control group) 		0/4   0/7 0 4
ref
S8075
R24646		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 6.14 [0.10;363.16] C 0/4   0/22 0 4
ref
S8146
R25046		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.31 [0.58;3.00]
excluded (control group) 		-/-   -/- - -
ref
S8142
R25018		 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.53 [0.70;3.35] -/-   53,634/1,440,631 53,625 -
ref
Total 2 studies 1.61 [0.75;3.47] 53,625 4
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 6.14[0.10; 363.16]044%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Cohen, 2019 2 1.53[0.70; 3.35]53,625-96%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.61[0.75; 3.47]53,62540.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.61[0.75; 3.47]53,62540%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.53[0.70; 3.35]53,625- -NACohen (Oxcarbazepine) (Controls unexposed NOS), 2019 1 unexposed, sickunexposed, sick 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 Tags Adjustment   - No  - No 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1   - Yes  - Yes 1.53[0.70; 3.35]53,625- -NACohen (Oxcarbazepine) (Controls unexposed NOS), 2019 1 All studiesAll studies 1.61[0.75; 3.47]53,62540%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8146, 8084

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.53[0.70; 3.35]53,625- -NACohen (Oxcarbazepine) (Controls unexposed NOS), 2019 1 unexposed, sick controlsunexposed, sick controls 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.33[0.59; 2.97]-40%NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 20.510.01.0